Actavis Launches Generic Viagra in Europe

Actavis, Inc.

, a leading global specialty pharmaceutical company, today announced that it has launched Sildenafil Actavis 25 mg, 50 mg and 100 mg tablets in 11 major Western-European markets on market formation.  Sildenafil Actavis, the generic equivalent of Pfizer's Viagra®, is prescribed to treat erectile dysfunction. Actavis' product was launched immediately after the patents expired in Austria, Denmark, France, Germany, Ireland, Italy, The Netherlands, Spain, Sweden, Switzerland and the United Kingdom. Actavis first launched Sildenafil tablets in Bulgaria in June 2009 - the first generic Sildenafil to enter the patent-free Bulgarian market - and has since launched the product in various other patent-free markets in Europe, including Iceland and Malta.  Sildenafil Actavis is manufactured and developed by Actavis, in Malta and Iceland respectively. According to IMS Health, Viagra® had sales of EUR382.2 million in Europe for the 12 months ending March 31, 2013. About ActavisActavis, Inc.

is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. Actavis has global headquarters in Parsippany, New Jersey, USA. Operating as Actavis Pharma, Actavis develops,